MX2020013772A - Composiciones y métodos para el tratamiento de la neuropatía óptica hereditaria de leber. - Google Patents
Composiciones y métodos para el tratamiento de la neuropatía óptica hereditaria de leber.Info
- Publication number
- MX2020013772A MX2020013772A MX2020013772A MX2020013772A MX2020013772A MX 2020013772 A MX2020013772 A MX 2020013772A MX 2020013772 A MX2020013772 A MX 2020013772A MX 2020013772 A MX2020013772 A MX 2020013772A MX 2020013772 A MX2020013772 A MX 2020013772A
- Authority
- MX
- Mexico
- Prior art keywords
- optic neuropathy
- hereditary optic
- compositions
- methods
- nucleic acid
- Prior art date
Links
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 title abstract 3
- 201000000639 Leber hereditary optic neuropathy Diseases 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title 1
- 102000006404 Mitochondrial Proteins Human genes 0.000 abstract 3
- 108010058682 Mitochondrial Proteins Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 108091026890 Coding region Proteins 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 108020005345 3' Untranslated Regions Proteins 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 230000002438 mitochondrial effect Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/664—Amides of phosphorus acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y106/00—Oxidoreductases acting on NADH or NADPH (1.6)
- C12Y106/99—Oxidoreductases acting on NADH or NADPH (1.6) with other acceptors (1.6.99)
- C12Y106/99003—NADH dehydrogenase (1.6.99.3)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/107—Rabbit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/07—Fusion polypeptide containing a localisation/targetting motif containing a mitochondrial localisation signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
En la presente se describe un ácido nucleico recombinante, que comprende: una secuencia de direccionamiento mitocondrial; una secuencia codificante de la proteína mitocondrial, en donde dicha secuencia codificante de la proteína mitocondrial codifica un polipéptido que comprende una proteína mitocondrial; y una secuencia de ácido nucleico 3'UTR. También se describe una composición farmacéutica que comprende el ácido nucleico recombinante y un método para tratar la neuropatía óptica hereditaria de Leber (LHON) mediante el uso de la composición farmacéutica.
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810702492.7A CN110656117A (zh) | 2018-06-29 | 2018-06-29 | 一种编码人nadh脱氢酶亚单位6蛋白的核酸及其应用 |
CN201810703168.7A CN110724695A (zh) | 2018-06-29 | 2018-06-29 | 一种编码人nadh脱氢酶亚单位1蛋白的核酸及其应用 |
PCT/CN2018/095023 WO2020010491A1 (zh) | 2018-07-09 | 2018-07-09 | 编码人nadh脱氢酶亚单位4蛋白的核酸及其应用 |
CN201810948193.1A CN110846392A (zh) | 2018-08-20 | 2018-08-20 | 一种重组腺相关病毒或含其的试剂盒及其应用 |
PCT/CN2018/103937 WO2020000641A1 (zh) | 2018-06-29 | 2018-09-04 | 编码人nadh脱氢酶亚单位蛋白的核酸及其应用 |
CN201811221305.XA CN111073899B (zh) | 2018-10-19 | 2018-10-19 | 一种编码人nadh脱氢酶亚单位4蛋白的核酸及其应用 |
CN201811230856.2A CN111068071A (zh) | 2018-10-22 | 2018-10-22 | 基因治疗Leber遗传学视神经病变 |
PCT/CN2018/113799 WO2020082417A1 (zh) | 2018-10-22 | 2018-11-02 | 基因治疗Leber遗传性视神经病变 |
PCT/CN2018/118662 WO2020077756A1 (zh) | 2018-10-19 | 2018-11-30 | Nd4蛋白的编码序列及其应用 |
PCT/CN2019/070461 WO2020037938A1 (zh) | 2018-08-20 | 2019-01-04 | 一种重组腺相关病毒或含其的试剂盒及其应用 |
PCT/CN2019/094136 WO2020001657A1 (en) | 2018-06-29 | 2019-07-01 | Compositions and methods for treating leber's hereditary optic neuropathy |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020013772A true MX2020013772A (es) | 2021-05-27 |
Family
ID=72041345
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020013772A MX2020013772A (es) | 2018-06-29 | 2019-07-01 | Composiciones y métodos para el tratamiento de la neuropatía óptica hereditaria de leber. |
Country Status (9)
Country | Link |
---|---|
US (3) | US11034954B2 (es) |
EP (1) | EP3814492A4 (es) |
JP (2) | JP2021529001A (es) |
KR (2) | KR102627561B1 (es) |
AU (3) | AU2019296451B2 (es) |
BR (1) | BR112020026361A2 (es) |
CA (1) | CA3103740A1 (es) |
MX (1) | MX2020013772A (es) |
SG (1) | SG11202012044QA (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11202012044QA (en) | 2018-06-29 | 2021-01-28 | Wuhan Neurophth Biological Tech Limited Company | Compositions and methods for treating leber's hereditary optic neuropathy |
CA3109432A1 (en) * | 2018-08-20 | 2020-02-27 | Wuhan Neurophth Biotechnology Limited Company | Compositions and methods for treating leber's hereditary optic neuropathy |
CN113025633A (zh) | 2019-12-09 | 2021-06-25 | 武汉纽福斯生物科技有限公司 | 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用 |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3625214A (en) | 1970-05-18 | 1971-12-07 | Alza Corp | Drug-delivery device |
US4906474A (en) | 1983-03-22 | 1990-03-06 | Massachusetts Institute Of Technology | Bioerodible polyanhydrides for controlled drug delivery |
US4789734A (en) | 1985-08-06 | 1988-12-06 | La Jolla Cancer Research Foundation | Vitronectin specific cell receptor derived from mammalian mesenchymal tissue |
JP2876058B2 (ja) | 1986-08-18 | 1999-03-31 | エミスフィア・テクノロジーズ・インコーポレイテッド | 薬物送達システム |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
US6024983A (en) | 1986-10-24 | 2000-02-15 | Southern Research Institute | Composition for delivering bioactive agents for immune response and its preparation |
US4897268A (en) | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
EP0678034B1 (en) | 1993-01-11 | 1999-05-26 | Dana Farber Cancer Institute | Inducing cytotoxic t lymphocyte responses |
WO1997039776A1 (en) | 1996-04-19 | 1997-10-30 | Genetic Therapy, Inc. | Gene therapy involving concurrent and repeated administration of adenoviruses and immunosuppressive agents |
US6207392B1 (en) | 1997-11-25 | 2001-03-27 | The Regents Of The University Of California | Semiconductor nanocrystal probes for biological applications and process for making and using such probes |
US20010006948A1 (en) * | 1998-11-25 | 2001-07-05 | James D. Kang | Gene transfer to intervertebral disc cells |
JP2004501608A (ja) | 2000-03-21 | 2004-01-22 | キュラゲン コーポレイション | Vegf調節遺伝子及びそれらを利用する方法 |
CA2442670A1 (en) | 2001-04-13 | 2002-10-24 | The Trustees Of The University Of Pennsylvania | Method of treating or retarding the development of blindness |
US20040072774A1 (en) * | 2002-02-23 | 2004-04-15 | Giovanni Manfredi | Methods for expressing and targeting mitochondrial-DNA-encoded peptides and uses thereof |
US7405284B2 (en) * | 2002-10-18 | 2008-07-29 | University Of Florida Research Foundation, Inc. | Reducing cellular dysfunction caused by mitochondrial gene mutations |
ES2647477T3 (es) * | 2004-06-01 | 2017-12-21 | Genzyme Corporation | Composiciones y métodos para prevenir la agregación del vector AAV |
US20130022979A1 (en) | 2005-04-18 | 2013-01-24 | Genesis Genomics Inc. | 3.4kb MITOCHONDRIAL DNA DELETION FOR USE IN THE DETECTION OF CANCER |
WO2006117250A2 (en) | 2005-05-03 | 2006-11-09 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Importation of mitochondrial protein by an enhanced allotopic approach |
EP2089412A4 (en) | 2006-10-23 | 2010-01-27 | John Guy | SUPPRESSION OF OXIDATIVE STRESS OF MITOCHONDRIEN |
US20100022517A1 (en) * | 2006-12-18 | 2010-01-28 | Richards Lori A | Ophthalmic formulation of rho kinase inhibitor compound |
JP2010538244A (ja) | 2007-06-20 | 2010-12-09 | ガラパゴス・ナムローゼ・フェンノートシャップ | 骨及び関節の変性疾患の治療に有用な分子標的及び化合物並びにその同定方法 |
DK2350279T3 (en) | 2008-10-22 | 2016-02-15 | Quark Pharmaceuticals Inc | METHODS OF TREATING EYE DISEASES |
BR112012018899A2 (pt) | 2010-01-28 | 2015-09-15 | Philadelphia Children Hospital | "método para purificar partículas de vetor de vírus adeno-associado." |
CN102517304B (zh) | 2011-12-16 | 2013-08-28 | 中国农业科学院生物技术研究所 | 重组葡萄糖氧化酶的优化基因及其表达载体和应用 |
US20160289674A1 (en) | 2012-04-02 | 2016-10-06 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of membrane proteins |
WO2013151669A1 (en) * | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
CN102634527B (zh) | 2012-04-11 | 2013-11-06 | 华中科技大学同济医学院附属同济医院 | 重组人nadh脱氢酶亚单位4基因及其表达载体构建方法 |
TWI690322B (zh) | 2012-10-02 | 2020-04-11 | 法商傳斯堅公司 | 含病毒的調配物及其使用 |
US9066966B2 (en) * | 2013-02-01 | 2015-06-30 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Methods and pharmaceutical compositions for the treatment of cardiomyopathy due to friedreich ataxia |
US9567376B2 (en) * | 2013-02-08 | 2017-02-14 | The Trustees Of The University Of Pennsylvania | Enhanced AAV-mediated gene transfer for retinal therapies |
EP2992892A1 (en) * | 2014-09-05 | 2016-03-09 | Universität zu Köln | Fusion protein for use in the treatment of mitochondrial diseases |
JP2017530968A (ja) | 2014-09-17 | 2017-10-19 | ユニバーシティー オブ アイオワ リサーチ ファンデーション | 免疫調整剤およびワクチン構成要素としてのウイルスrnaセグメント |
CN104450747B (zh) * | 2014-09-23 | 2018-02-09 | 武汉纽福斯生物科技有限公司 | 用于治疗Leber遗传性视神经病变的重组腺相关病毒‑NADH脱氢酶亚单位4基因全长以及药剂 |
JP2018521000A (ja) * | 2015-05-29 | 2018-08-02 | シドネキシス,インク. | D2oで安定化された医薬製剤 |
WO2017011519A1 (en) | 2015-07-13 | 2017-01-19 | Sangamo Biosciences, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
WO2018102672A1 (en) | 2016-12-04 | 2018-06-07 | Alavi Khorassani Moghadam Marcel Victor | Methods for treating diseases related to mitochondrial stress |
US20180207293A1 (en) | 2017-01-25 | 2018-07-26 | 2C Tech Corp. | Nanoparticles for sustained ophthalmic drug delivery and methods of use |
KR20230093072A (ko) * | 2017-03-01 | 2023-06-26 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 안구 장애에 대한 유전자 치료 |
AU2018314280B2 (en) | 2017-08-11 | 2023-07-20 | Rsem, Société En Commandite | Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells |
WO2019204304A2 (en) | 2018-04-16 | 2019-10-24 | The Children's Hospital Of Philadelphia | Mitochondrial rna import for treating mitochondrial disease |
WO2019241206A1 (en) | 2018-06-11 | 2019-12-19 | Gensight Biologics Sa | Recombinant aav vectors and methods of using the same |
CN110846392A (zh) | 2018-08-20 | 2020-02-28 | 武汉纽福斯生物科技有限公司 | 一种重组腺相关病毒或含其的试剂盒及其应用 |
CN111068071A (zh) | 2018-10-22 | 2020-04-28 | 武汉纽福斯生物科技有限公司 | 基因治疗Leber遗传学视神经病变 |
WO2020010491A1 (zh) | 2018-07-09 | 2020-01-16 | 武汉纽福斯生物科技有限公司 | 编码人nadh脱氢酶亚单位4蛋白的核酸及其应用 |
SG11202012044QA (en) | 2018-06-29 | 2021-01-28 | Wuhan Neurophth Biological Tech Limited Company | Compositions and methods for treating leber's hereditary optic neuropathy |
CN111073899B (zh) | 2018-10-19 | 2021-01-01 | 武汉纽福斯生物科技有限公司 | 一种编码人nadh脱氢酶亚单位4蛋白的核酸及其应用 |
CA3109432A1 (en) | 2018-08-20 | 2020-02-27 | Wuhan Neurophth Biotechnology Limited Company | Compositions and methods for treating leber's hereditary optic neuropathy |
WO2020038352A1 (en) | 2018-08-20 | 2020-02-27 | Wuhan Neurophth Biological Technology Limited Company | Compositions and methods for treating leber's hereditary optic neuropathy |
CN113025633A (zh) | 2019-12-09 | 2021-06-25 | 武汉纽福斯生物科技有限公司 | 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用 |
-
2019
- 2019-07-01 SG SG11202012044QA patent/SG11202012044QA/en unknown
- 2019-07-01 BR BR112020026361-3A patent/BR112020026361A2/pt unknown
- 2019-07-01 AU AU2019296451A patent/AU2019296451B2/en active Active
- 2019-07-01 KR KR1020217001385A patent/KR102627561B1/ko active IP Right Grant
- 2019-07-01 JP JP2021521870A patent/JP2021529001A/ja active Pending
- 2019-07-01 CA CA3103740A patent/CA3103740A1/en active Pending
- 2019-07-01 KR KR1020247001775A patent/KR20240014102A/ko active Application Filing
- 2019-07-01 EP EP19826653.8A patent/EP3814492A4/en active Pending
- 2019-07-01 MX MX2020013772A patent/MX2020013772A/es unknown
-
2020
- 2020-03-31 US US16/836,644 patent/US11034954B2/en active Active
-
2021
- 2021-05-11 US US17/317,295 patent/US20220340895A1/en active Pending
- 2021-05-14 US US17/320,388 patent/US11332741B1/en active Active
- 2021-07-05 AU AU2021204690A patent/AU2021204690A1/en not_active Abandoned
-
2023
- 2023-02-28 JP JP2023029170A patent/JP2023078173A/ja active Pending
- 2023-12-20 AU AU2023285773A patent/AU2023285773A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2023285773A1 (en) | 2024-01-18 |
AU2019296451B2 (en) | 2021-04-29 |
EP3814492A1 (en) | 2021-05-05 |
US20220340895A1 (en) | 2022-10-27 |
BR112020026361A2 (pt) | 2021-03-30 |
AU2019296451A1 (en) | 2021-01-07 |
US20200263172A1 (en) | 2020-08-20 |
AU2021204690A1 (en) | 2021-07-29 |
JP2023078173A (ja) | 2023-06-06 |
US11034954B2 (en) | 2021-06-15 |
US11332741B1 (en) | 2022-05-17 |
SG11202012044QA (en) | 2021-01-28 |
KR20210027374A (ko) | 2021-03-10 |
KR20240014102A (ko) | 2024-01-31 |
KR102627561B1 (ko) | 2024-01-24 |
CA3103740A1 (en) | 2020-01-02 |
EP3814492A4 (en) | 2022-02-23 |
JP2021529001A (ja) | 2021-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020013772A (es) | Composiciones y métodos para el tratamiento de la neuropatía óptica hereditaria de leber. | |
MX2022006949A (es) | Composiciones y metodos para tratar la neuropatia optica hereditaria de leber con proteinas nadh deshidrogenasa. | |
BR112022019782A2 (pt) | Construtos de rna e usos dos mesmos | |
MY191030A (en) | Gdf15 fusion proteins and uses thereof | |
MX2021014007A (es) | Proteinas de union a epcam y metodos de uso. | |
MX2018010824A (es) | Proteinas de union inducibles y metodos de uso. | |
MX2020010871A (es) | Compuestos de 5'-caperuza-trinucleótidos u oligonucleótidos superiores y sus usos en estabilizar arn, que expresan proteínas y en la terapia. | |
AR002832A1 (es) | Haloperoxidasas obtenidas de curvularia verruculosa, acidos nucleicos que las codifican, vector recombinante, celula huesped recombinante, metodos paraproducir dichas haloperoxidasas, metodo para oxidar un ion haluro, metodo para halogenar un compuesto y metodo para matar celulas microbianas o inhibir su | |
BR112021025928A2 (pt) | Métodos de preparação de ácido bempedoico e composições do mesmo | |
BR112021014255A2 (pt) | Molécula de ácido nucleico, composição, e, método de prevenção ou tratamento de uma doença ou distúrbio | |
MX2022010175A (es) | Proteinas de union a flt3 y metodos de uso. | |
MX2019006515A (es) | Composiciones que comprenden peptido wkdeagkplvk. | |
MX2021013743A (es) | Subunidad s1 modificada de la proteina de espicula de coronavirus. | |
WO2018155813A3 (ko) | 엔테로코쿠스 패슘에 대하여 용균력을 가지는 신규한 항균단백질 efal-2 | |
PE20210918A1 (es) | Composiciones y metodos para el tratamiento de la distrofia macular | |
MX2020009522A (es) | Anticuerpos anti-folato del receptor 1 y usos de los mismos. | |
MX2022007546A (es) | Interferon-alfa-2 modificado que tiene inmunogenicidad reducida. | |
WO2021087296A8 (en) | Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems | |
EP4079750A3 (en) | Adenoviruses and methods for using adenoviruses | |
MX2023006148A (es) | Polipeptidos que eligen como objetivo a dr4 y/o dr5 y composiciones y metodos relacionados. | |
MX2021004907A (es) | Vacuna de ibv 4/91 con proteina espicular heterologa. | |
AU2018347511A8 (en) | Periodontitis vaccine and related compositions and method of use | |
MX2021011754A (es) | Composiciones, dispositivos y metodos para el tratamiento de la enfermedad de fabry. | |
MX2021004859A (es) | Vacuna de ibv h52 con proteina espicular heterologa. | |
ES2159306T3 (es) | Vacuna contra coccidiosis en pollos. |